10 Apr 2019

CAN SOMEONE TELL ME WHAT A PBM REALLY DOES?

By Rachel Bluth   It was back-to-school day at the Senate Finance Committee hearing April 9. In the third of a series of hearings on rising drug prices, the senators seemed focused on getting an answer to one central question: What the heck is a pharmacy benefit manager? Pharmacy benefit managers,

0
10 Apr 2019

Teleflex gets premarket OK for biomechanical MANTA Closure

  Teleflex Inc., a global provider of medical technologies for critical care and surgery, has announced that it received premarket approval from the U.S. Food and Drug Administration for the MANTA Vascular Closure Device – the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial

0
10 Apr 2019

SVS JOURNAL: EVT IS THE NEW CASH COW FOR NON-VASCULAR DOCTORS; ETHICAL ISSUES RAISED

A new report suggests that providers who are not traditionally associated with the treatment of venous disease are driving the rapid increase in endovenous therapies. A compound annual growth rate of 15 percent has been observed for minimally-invasive procedures to treat superficial venous reflux over the past decade. In the

0
10 Apr 2019

LETHAL PLANS: When seniors turn to suicide in long-term care

      By Melissa Bailey and JoNel Aleccia When Larry Anders moved into the Bay at Burlington nursing home in late 2017, he wasn’t supposed to be there long. At 77, the stoic Wisconsin machinist had just endured the death of his wife of 51 years and a grim new diagnosis: throat

0
09 Apr 2019

 MERZ NORTH AMERICA REGAINS EXCLUSIVE DISTRIBUTION OF ASCLERA (POLIDOCANOL) INJECTION

  Merz North America Inc. has regained exclusive distribution of Asclera (polidocanol) Injection in the United States to all healthcare practitioners and phlebologists treating varicose veins, effective April 8. Also effective April 8th, AngioDynamics Inc. is no longer an authorized distributor of Asclera. All healthcare professionals will now be able

0
08 Apr 2019

HIMSS conference speaker Will Present Lessons Learned from a HIPAA Audit

Carol Amick, manager of Healthcare Services, will speaking at the Healthcare Information and Management Systems Society Annual Conference to be held April 24-25 in Raleigh, North Carolina. Amick will discuss HIPAA regulations and how healthcare organizations are still missing the mark when it comes to covering the basics of HIPAA

0
02 Apr 2019

VIVA PHYSICIANS: ATTEND SVM19 IN MCLEAN, VA, MAY 29-JUNE 1

Register for the SVM 2019 Annual Scientific Sessions, the premier meeting for vascular medicine professionals. This year the meeting will take place in McLean, VA, at the Ritz-Carlton Tysons Corner, minutes from Washington, DC, May 29 – June 1. Early-bird registration rates end Monday, April 8. This is a very

0
13 Mar 2019

HOW MUCH DIFFERENCE WILL ELI LILLY’S HALF-PRICE INSULIN MAKE?

  By Bram Sable-Smith When Erin Gilmer filled her insulin prescription at a Denver-area Walgreens in January, she paid $8.50. U.S. taxpayers paid another $280.51. “It eats at me to know that taxpayer money is being wasted,” said Gilmer, who has Medicare and was diagnosed with Type 1 diabetes while

0
11 Mar 2019

PATIENTS NEED TRANSPARENCY AND RELIEF FROM HIGH DRUG COSTS, NOT DEFENSE OF THE STATUS QUO

By: John O’Brien The current drug pricing system is broken and indefensible. Right now, everybody but the patient benefits as list prices climb higher and higher. President Trump has proposed to bring transparency to the system, end the status quo of kickbacks from drug companies to middlemen and plans, known in

0
06 Mar 2019

FIRST STEP: LILLY RELEASES HUMALOG GENERIC, SLASHING INSULIN LIST PRICE IN HALF

    Lilly has released Lispro, a generic form of its insulin drug of Humalog, cutting the list price in half and ideally reducing out-of-pocket patient costs. Insulin Lispro will go for $137.35 per vial or $265.50 for a pack of five KwikPens. Because Humalog and Lispro are fast-acting forms of insulin,

0